CV1-CAR T cells

CV1-CAR T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy developed by Seattle Children's Research Institute and the University of Washington for the treatment of solid tumors. The therapy utilizes a CAR construct with a binding domain derived from CV1, which is a high-affinity variant of the signal regulatory protein alpha (SIRPα) designed to target the 'don't eat me' signal protein CD47 overexpressed on tumor cells. Although the CV1-CAR T cells showed potent and specific cytotoxic activity against cancer cells in vitro, the development program was terminated after the cells failed to demonstrate anti-tumor efficacy in xenograft animal models. Mechanistic investigations found that the CAR-T cells downregulated their own surface CD47 expression to avoid fratricide (self-destruction); however, this lack of CD47 made the CAR-T cells susceptible to phagocytosis and clearance by macrophages in vivo, preventing the necessary persistence and expansion required for therapeutic effect.

Other names

CV1-SIRPα CAR-T cellsCD47-targeted CAR-T cell therapyCD-47-targeted CAR-T cell therapyCD 47-targeted CAR-T cell therapyCV1-based CAR-T cellsCV-1-based CAR-T cellsCV 1-based CAR-T cells